The DOI matches its Crossref record; 92 of the 92 references it cites were found in a registry or an index.
Mechanisms of resistance to EGFR tyrosine kinase inhibitors
Open accessAbstract
Since the discovery that non-small cell lung cancer (NSCLC) is driven by epidermal growth factor receptor (EGFR) mutations, the EGFR tyrosine kinase inhibitors (EGFR-TKIs, e.g., gefitinib and elrotinib) have been effectively used for clinical treatment. However, patients eventually develop drug resistance. Resistance to EGFR-TKIs is inevitable due to various mechanisms, such as the secondary mutation (T790M), activation of alternative pathways (c-Met, HGF, AXL), aberrance of the downstream pathways (K-RAS mutations, loss of PTEN), impairment of the EGFR-TKIs-mediated apoptosis pathway (BCL2-like 11/BIM deletion polymorphism), histologic transformation, ATP binding cassette (ABC) transporter effusion, etc. Here we review and summarize the known resistant mechanisms to EGFR-TKIs and provide potential targets for development of new therapeutic strategies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Epithelial–mesenchymal transitions in tumour progression
Thiery, J. P. (2002) · Nature Reviews Cancer · doi:10.1038/nrc822 · Cited by 6,628
Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
Soda, M., Choi, Y. L., Enomoto, M., Takada, S., Yamashita, Y., Ishikawa, S., Fujiwara, S.-I., Watanabe, H., Kurashina, K., Hatanaka, H., et al. (2007) · Nature · doi:10.1038/nature05945 · Cited by 5,439
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
Kwak, E. L., Bang, Y.-J., Camidge, D. R., Shaw, A. T., Solomon, B., Maki, R. G., Ou, S.-H. I., Dezube, B. J., Jänne, P. A., Costa, D. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1006448 · Cited by 4,446
EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964
Yu, H. A., Arcila, M. E., Rekhtman, N., Sima, C. S., Zakowski, M. F., Pao, W., Kris, M. G., Miller, V. A., Ladanyi, M., & Riely, G. J. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2246 · Cited by 2,454
Cross, D. A. E., Ashton, S. E., Ghiorghiu, S., Eberlein, C., Nebhan, C. A., Spitzler, P. J., Orme, J. P., Finlay, M. R. V., Ward, R. A., Mellor, M. J., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0337 · Cited by 2,246
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
Yun, C.-H., Mengwasser, K. E., Toms, A. V., Woo, M. S., Greulich, H., Wong, K.-K., Meyerson, M., & Eck, M. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709662105 · Cited by 2,118 · cited 2×
“com/locate/apsb Acta Pharmaceutica Sinica B Acta Pharmaceutica Sinica B 2015;5(5):390–401”
BackgroundEGFR Antagonists in Cancer Treatment
Ciardiello, F., & Tortora, G. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0707704 · Cited by 2,058
KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib
Pao, W., Wang, T. Y., Riely, G. J., Miller, V. A., Pan, Q., Ladanyi, M., Zakowski, M. F., Heelan, R. T., Kris, M. G., & Varmus, H. E. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020017 · Cited by 1,516
Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer
Zhang, Z., Lee, J. C., Lin, L., Olivas, V., Au, V., LaFramboise, T., Abdel-Rahman, M., Wang, X., Levine, A. D., Rho, J. K., et al. (2012) · Nature Genetics · doi:10.1038/ng.2330 · Cited by 1,224
Engelman, J. A., Zejnullahu, K., Gale, C.-M., Lifshits, E., Gonzales, A. J., Shimamura, T., Zhao, F., Vincent, P. W., Naumov, G. N., Bradner, J. E., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1885 · Cited by 730
Yano, S., Wang, W., Li, Q., Matsumoto, K., Sakurama, H., Nakamura, T., Ogino, H., Kakiuchi, S., Hanibuchi, M., Nishioka, Y., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1643 · Cited by 643
Walter, A. O., Sjin, R. T. T., Haringsma, H. J., Ohashi, K., Sun, J., Lee, K., Dubrovskiy, A., Labenski, M., Zhu, Z., Wang, Z., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0314 · Cited by 620
A Novel ALK Secondary Mutation and EGFR Signaling Cause Resistance to ALK Kinase Inhibitors
Sasaki, T., Koivunen, J., Ogino, A., Yanagita, M., Nikiforow, S., Zheng, W., Lathan, C., Marcoux, J. P., Du, J., Okuda, K., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1340 · Cited by 597
Ng, K. P., Hillmer, A. M., Chuah, C. T. H., Juan, W. C., Ko, T. K., Teo, A. S. M., Ariyaratne, P. N., Takahashi, N., Sawada, K., Fei, Y., et al. (2012) · Nature Medicine · doi:10.1038/nm.2713 · Cited by 557
Guix, M., Faber, A. C., Wang, S. E., Olivares, M. G., Song, Y., Qu, S., Rinehart, C., Seidel, B., Yee, D., Arteaga, C. L., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34588 · Cited by 521
Sos, M. L., Koker, M., Weir, B. A., Heynck, S., Rabinovsky, R., Zander, T., Seeger, J. M., Weiss, J., Fischer, F., Frommolt, P., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4055 · Cited by 504
Su, K.-Y., Chen, H.-Y., Li, K.-C., Kuo, M.-L., Yang, J. C.-H., Chan, W.-K., Ho, B.-C., Chang, G.-C., Shih, J.-Y., Yu, S.-L., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.3224 · Cited by 499
Costa, D. B., Halmos, B., Kumar, A., Schumer, S. T., Huberman, M. S., Boggon, T. J., Tenen, D. G., & Kobayashi, S. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040315 · Cited by 499
Epidermal growth factor receptor (EGFR) in lung cancer: an overview and update.
Bethune, G. C., Bethune, D. C. G., Ridgway, N. D., & Xu, Z. (2010) · Europe PMC (PubMed Central) · Cited by 469
Ohashi, K., Sequist, L. V., Arcila, M. E., Moran, T., Chmielecki, J., Lin, Y.-L., Pan, Y., Wang, L., de Stanchina, E., Shien, K., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1203530109 · Cited by 441
Yao, Z., Fenoglio, S., Gao, D. C., Camiolo, M., Stiles, B., Lindsted, T., Schlederer, M., Johns, C., Altorki, N., Mittal, V., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1009472107 · Cited by 389
STAT3 activation in response to IL-6 is prolonged by the binding of IL-6 receptor to EGF receptor
Wang, Y., van Boxel-Dezaire, A. H. H., Cheon, H., Yang, J., & Stark, G. R. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1315862110 · Cited by 327
Renewing the conspiracy theory debate: does Raf function alone to mediate Ras oncogenesis?
Repasky, G. A., Chenette, E. J., & Der, C. J. (2004) · Trends in Cell Biology · doi:10.1016/j.tcb.2004.09.014 · Cited by 300
Zhang, X., Zhang, S., Yang, X., Yang, J., Zhou, Q., Yin, L., An, S., Lin, J., Chen, S., Xie, Z., et al. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-188 · Cited by 296
Bean, J., Riely, G. J., Balak, M., Marks, J. L., Ladanyi, M., Miller, V. A., & Pao, W. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0151 · Cited by 278
An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation
Schoeberl, B., Faber, A. C., Li, D., Liang, M.-C., Crosby, K., Onsum, M., Burenkova, O., Pace, E., Walton, Z., Nie, L., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3145 · Cited by 264
Hoeflich, K. P., Merchant, M., Orr, C., Chan, J., Den Otter, D., Berry, L., Kasman, I., Koeppen, H., Rice, K., Yang, N.-Y., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-1515 · Cited by 242
EGFR T790M Mutation: A Double Role in Lung Cancer Cell Survival?
Suda, K., Onozato, R., Yatabe, Y., & Mitsudomi, T. (2009) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181913c9f · Cited by 226
Reduced NF1 Expression Confers Resistance to EGFR Inhibition in Lung Cancer
de Bruin, E. C., Cowell, C., Warne, P. H., Jiang, M., Saunders, R. E., Melnick, M. A., Gettinger, S., Walther, Z., Wurtz, A., Heynen, G. J., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0741 · Cited by 203
Kim, S. M., Kwon, O.-J., Hong, Y. K., Kim, J. H., Solca, F., Ha, S.-J., Soo, R. A., Christensen, J. G., Lee, J. H., & Cho, B. C. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0311 · Cited by 202
Tumor VEGF:VEGFR2 autocrine feed-forward loop triggers angiogenesis in lung cancer
Chatterjee, S., Heukamp, L. C., Siobal, M., Schöttle, J., Wieczorek, C., Peifer, M., Frasca, D., Koker, M., König, K., Meder, L., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci65385 · Cited by 195
Erlotinib Resistance in Lung Cancer Cells Mediated by Integrin β1/Src/Akt-Driven Bypass Signaling
Kanda, R., Kawahara, A., Watari, K., Murakami, Y., Sonoda, K., Maeda, M., Fujita, H., Kage, M., Uramoto, H., Costa, C., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4502 · Cited by 173
Sildenafil Reverses ABCB1- and ABCG2-Mediated Chemotherapeutic Drug Resistance
Shi, Z., Tiwari, A. K., Shukla, S., Robey, R. W., Singh, S., Kim, I.-W., Bates, S. E., Peng, X., Abraham, I., Ambudkar, S. V., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3820 · Cited by 170
Self-citationEGFRvIII promotes glioma angiogenesis and growth through the NF-κB, interleukin-8 pathway
Bonavia, R., Inda, M. M., Vandenberg, S., Cheng, S.-Y., Nagane, M., Hadwiger, P., Tan, P., Sah, D. W. Y., Cavenee, W. K., & Furnari, F. B. (2012) · Oncogene · doi:10.1038/onc.2011.563 · Cited by 170
Influence of IL-8 on The Epithelial–Mesenchymal Transition and the Tumor Microenvironment
Palena, C., Hamilton, D. H., & Fernando, R. I. (2012) · Future Oncology · doi:10.2217/fon.12.59 · Cited by 166
β1 integrin mediates an alternative survival pathway in breast cancer cells resistant to lapatinib
Huang, C., Park, C. C., Hilsenbeck, S. G., Ward, R., Rimawi, M. F., Wang, Y.-C., Shou, J., Bissell, M. J., Osborne, C. K., & Schiff, R. (2011) · Breast Cancer Research · doi:10.1186/bcr2936 · Cited by 165
Wang, L., Hu, H., Pan, Y., Wang, R., Li, Y., Shen, L., Yu, Y., Li, H., Cai, D., Sun, Y., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0088291 · Cited by 164
T790M and acquired resistance of EGFR TKI: a literature review of clinical reports.
Ma, C., Wei, S., & Song, Y. J. (2011) · PubMed · doi:10.3978/j.issn.2072-1439.2010.12.02 · Cited by 158
Xia, W., Petricoin, E., Zhao, S., Liu, L.-H., Osada, T., Cheng, Q., Wulfkuhle, J. D., Gwin, W. R., Yang, X., Gallagher, R. I., et al. (2013) · Breast Cancer Research · doi:10.1186/bcr3480 · Cited by 153
Bae, G.-Y., Choi, S., Lee, J., Jo, J., Lee, J., Kim, J., & Cha, H. (2013) · Oncotarget · doi:10.18632/oncotarget.1463 · Cited by 149
Bianco, R., Rosa, R., Damiano, V., Daniele, G., Gelardi, T., Garofalo, S., Tarallo, V., De Falco, S., Melisi, D., Benelli, R., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4905 · Cited by 149
Overcoming EMT-associated resistance to anti-cancer drugs via Src/FAK pathway inhibition
WILSON, C. A., Nicholes, K., Bustos, D. J., Lin, E., Song, Q., Stéphan, J.-P., Kirkpatrick, D. S., & Settleman, J. (2014) · Oncotarget · doi:10.18632/oncotarget.2397 · Cited by 149
Ware, K. E., Marshall, M. E., Heasley, L. R., Marek, L. A., Hinz, T. K., Hercule, P., Helfrich, B. A., Doebele, R. C., & Heasley, L. E. (2010) · PLoS ONE · doi:10.1371/journal.pone.0014117 · Cited by 148
Rho, J. K., Choi, Y. J., Kim, S. Y., Kim, T. W., Choi, E. K., Yoon, S.-J., Park, B. M., Park, E., Bae, J. H., Choi, C., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1103 · Cited by 146
Akhavan, D., Pourzia, A. L., Nourian, A. A., Williams, K. J., Nathanson, D. A., Babić, I., Villa, G. R., Tanaka, K., Nael, A., Yang, H., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0502 · Cited by 145
Kubo, T., Yamamoto, H., Lockwood, W. W., Valencia, I., Soh, J., Peyton, M., Jida, M., Otani, H., Fujii, T., Ouchida, M., et al. (2008) · International Journal of Cancer · doi:10.1002/ijc.24150 · Cited by 143
The Tumor Microenvironment in Non–Small-Cell Lung Cancer
Graves, E. E., Maity, A. M., & Le, Q. (2010) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2010.01.003 · Cited by 142
Cheung, H. W., Du, J., Boehm, J. S., He, F., Weir, B. A., Wang, X., Butaney, M., Sequist, L. V. D., Luo, B., Engelman, J. A., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0046 · Cited by 132
Yamada, T., Takeuchi, S., Nakade, J., Kita, K., Nakagawa, T., Nanjo, S., Nakamura, T., Matsumoto, K., Soda, M., Mano, H., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2972 · Cited by 122
CRIPTO1 expression in EGFR-mutant NSCLC elicits intrinsic EGFR-inhibitor resistance
Park, K.-S., Raffeld, M. A., Moon, Y. W., Xi, L., Bianco, C., Pham, T. C., Lee, L. C., Mitsudomi, T., Yatabe, Y., Okamoto, I., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci73048 · Cited by 122
Fujita, Y., Suda, K., Kimura, H., Matsumoto, K., Arao, T., Nagai, T., Saijo, N., Yatabe, Y., Mitsudomi, T., & Nishio, K. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182653d7f · Cited by 121
Mueller, K. L., Madden, J. M., Zoratti, G. L., Kuperwasser, C., List, K., & Boerner, J. L. (2012) · Breast Cancer Research · doi:10.1186/bcr3224 · Cited by 115
Azuma, K., Kawahara, A., Sonoda, K., Nakashima, K., Tashiro, K., Watari, K., Izumi, H., Kage, M., Kuwano, M., Ono, M., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.1866 · Cited by 108
Xie, M., He, C.-S., Wei, S., & Zhang, L. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.07.007 · Cited by 107
Song, L., Smith, M. A., Doshi, P. D., Sasser, K., Fulp, W. J., Altiok, S., & Haura, E. B. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000193 · Cited by 101
Kim, S. M., Yun, M. R., Hong, Y. K., Solca, F., Kim, J.-H., Kim, H. J., & Cho, B. C. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-1188 · Cited by 100
Katanasaka, Y., Kodera, Y., Kitamura, Y., Morimoto, T., Tamura, T., & Koizumi, F. (2013) · Molecular Cancer · doi:10.1186/1476-4598-12-31 · Cited by 99
Peled, N., Wynes, M. W., Ikeda, N., Ohira, T., Yoshida, K., Qian, J., Ilouze, M., Brenner, R. M., Kato, Y., Mascaux, C., et al. (2013) · Cellular Oncology · doi:10.1007/s13402-013-0133-9 · Cited by 93
Pérez-Torres, M., Guix, M., González, A., & Arteaga, C. L. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m607958200 · Cited by 89
Sox9 mediates Notch1-induced mesenchymal features in lung adenocarcinoma
Capaccione, K. M., Hong, X., Morgan, K. M., Liu, W., Bishop, M. J., Liu, L., Markert, E. K., Deen, M. F., Minerowicz, C., Bertino, J. R., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.1970 · Cited by 82
Ju, L., Zhou, C., Li, W., & Yan, L. (2010) · Journal of Cellular Biochemistry · doi:10.1002/jcb.22888 · Cited by 75
Landi, L. M., & Cappuzzo, F. (2013) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2013.846830 · Cited by 74
Hong, Z., Cao, X., Li, N., Zhang, Y., Lan, L., Zhou, Y., Pan, X., Shen, L., Yin, Z., & Luo, L. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12610 · Cited by 72
K-RAS Mutant Pancreatic Tumors Show Higher Sensitivity to MEK than to PI3K Inhibition In Vivo
Hofmann, I., Weiss, A., Elain, G., Schwaederle, M. C., Sterker, D., Romanet, V., Schmelzle, T., Lai, A., Brachmann, S. M., Bentires‐Alj, M., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0044146 · Cited by 72
Sodani, K. S., Tiwari, A. K., Singh, S., Patel, A. S., Xiao, Z., Chen, J.-J., Sun, Y.-L., Talele, T. T., & Chen, Z. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.02.028 · Cited by 60
Correlation of PIK3Ca mutations with gene expression and drug sensitivity in NCI-60 cell lines
Whyte, D. B., & Holbeck, S. L. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.12.025 · Cited by 60
Rationale for targeting VEGF, FGF, and PDGF for the treatment of NSCLC
Ballas, & Chachoua (2011) · OncoTargets and Therapy · doi:10.2147/ott.s18155 · Cited by 57
Nakade, J., Takeuchi, S., Nakagawa, T., Ishikawa, D., Sano, T., Nanjo, S., Yamada, T., Ebi, H., Zhao, L., Yasumoto, K., et al. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000170 · Cited by 51
Kim, E. J., Jeong, J., Bae, S., Kang, S., Kim, C. H., & Lim, Y. (2012) · Journal of Cellular Biochemistry · doi:10.1002/jcb.24465 · Cited by 50
CRKL promotes lung cancer cell invasion through ERK‐MMP9 pathway
Fu, L., Chengyao, X., Li, Q., Qianze, D., Enhua, W., & Wang, Y. (2014) · Molecular Carcinogenesis · doi:10.1002/mc.22148 · Cited by 49
Self-citationNanjo, S., Yamada, T., Nishihara, H., Takeuchi, S., Sano, T., Nakagawa, T., Ishikawa, D., Zhao, L., Ebi, H., Yasumoto, K., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0084700 · Cited by 45
Ishiguro, Y., Ishiguro, H., & Miyamoto, H. (2013) · Oncotarget · doi:10.18632/oncotarget.939 · Cited by 43
de Mello, R. A., Marques, D. S., Medeiros, R., & Araújo, A. M. (2011) · World Journal of Clinical Oncology · doi:10.5306/wjco.v2.i11.367 · Cited by 43
Lee, Y., Lee, M.-R., & Kim, S. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.03.082 · Cited by 40
Ju, L., & Zhou, C. (2013) · Cancer Cell International · doi:10.1186/1475-2867-13-15 · Cited by 40
Modeling of Tumor Progression in NSCLC and Intrinsic Resistance to TKI in Loss of PTEN Expression
Bidkhori, G., Moeini, A., & Masoudi‐Nejad, A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0048004 · Cited by 38
Kiyota, M., Kuroda, J., Yamamoto‐Sugitani, M., Shimura, Y., Nakayama, R., Nagoshi, H., Mizutani, S., Chinen, Y., Sasaki, N., Sakamoto, N., et al. (2013) · APOPTOSIS · doi:10.1007/s10495-013-0882-y · Cited by 36
Xu, M., Mao, G., Liu, J., Li, J.-C., Huang, H., Liu, Y., & Liu, J. (2014) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2014.15.9.4013 · Cited by 36
Smith, D. L., Acquaviva, J., Sequeira, M., Jimenez, J.-P., Zhang, C., Sang, J., Bates, R. C., & Proia, D. A. (2014) · Targeted Oncology · doi:10.1007/s11523-014-0329-6 · Cited by 35
Woo, H. S., Ahn, H. K., Lee, H. Y., Park, I., Kim, Y. S., Hong, J., Sym, S. J., Park, J., Lee, J. H., Shin, D. B., et al. (2014) · Investigational New Drugs · doi:10.1007/s10637-014-0146-x · Cited by 31
Ren, H. J., Zhao, L., Li, Y., Yue, P., Deng, X., Owonikoko, T. K., Chen, M., Khuri, F. R., & Sun, S. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.03.032 · Cited by 29
The Epidermal Growth Factor Receptor D761Y Mutation and Effect of Tyrosine Kinase Inhibitor
Toyooka, S., Date, H., Uchida, A., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0070 · Cited by 23
Dabrafenib for the treatment ofBRAFV600-positive melanoma: a safety evaluation
Rutkowski, P. L., & Blank, C. U. (2014) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2014.939954 · Cited by 20
Sarkar, S., Rajput, S., Tripathi, A. K., & Mandal, M. (2013) · Molecular Cancer · doi:10.1186/1476-4598-12-122 · Cited by 20
Nakata, S., Tanaka, H., Ito, Y., Hara, M., Fujita, M., Kondo, E., Kanemitsu, Y., Yatabe, Y., & Nakanishi, H. (2014) · International Journal of Oncology · doi:10.3892/ijo.2014.2538 · Cited by 15
Hong, Y., Jang, W., Chun, K., & Jeong, C. (2014) · Oncology Reports · doi:10.3892/or.2014.3161 · Cited by 13
Suda, K., Mizuuchi, H., Murakami, I., Uramoto, H., Tanaka, F., Sato, K., Takemoto, T., Iwasaki, T., Sekido, Y., Yatabe, Y., et al. (2014) · Lung Cancer · doi:10.1016/j.lungcan.2014.05.018 · Cited by 13
Targeted therapy for NSCLC: ALK inhibition
Pearson, R., & Kolesar, J. (2011) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155211417477 · Cited by 8
Khan, N. A., Mirshahidi, S., & Mirshahidi, H. (2014) · Case Reports in Oncology · doi:10.1159/000365325 · Cited by 6
Brown, W. S., & Wendt, M. K. (2014) · Breast Cancer Research · doi:10.1186/s13058-014-0448-0 · Cited by 6
Cited by
Jacob, F., Salinas, R. D., Zhang, D. Y., Nguyen, P. T. T., Schnoll, J. G., Wong, S. Z. H., Thokala, R., Sheikh, S., Saxena, D., Prokop, S., et al. (2020) · Cell · doi:10.1016/j.cell.2019.11.036 · Cited by 1,149
Cell death-based treatment of lung adenocarcinoma
Denisenko, T. V., Budkevich, I. N., & Zhivotovsky, B. (2018) · Cell Death & Disease · doi:10.1038/s41419-017-0063-y · Cited by 768
Sabbah, D. A., Hajjo, R., & Sweidan, K. (2020) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026620666200303123102 · Cited by 591
Hassell, B. A., Goyal, G., Lee, E., Sontheimer-Phelps, A., Levy, O., Chen, C. S., & Ingber, D. E. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.09.043 · Cited by 467
Targeting cytokine and chemokine signaling pathways for cancer therapy
Yi, M., Li, T., Niu, M., Zhang, H., Wu, Y., Wu, K., & Dai, Z. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01868-3 · Cited by 455
Metadata
- Authors
- Huang, L., & Fu, L.
- Venue
- Acta Pharmaceutica Sinica B
- Publisher
- Elsevier BV
- Published
- 2015-09
- Volume
- 5
- Issue
- 5
- Pages
- 390-401
- ISSN
- 2211-3835 (ISSN-L)
- OpenAlex
- W950232622
- Cited by
- 585
- References
- 92
- FWCI
- 32.35
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.